Zai Lab
Robert J. Brown, MD, currently serves as the Chief Medical Officer of Oncology at Zai Lab, a position held since September 2023. Prior to this role, Robert held multiple senior positions in clinical development at Nurix Therapeutics from June 2020 to September 2023, including Executive Vice President. Experience also includes leadership roles at Allogene Therapeutics and Aduro Biotech, as well as Executive Medical Director at Iovance Biotherapeutics, focusing on tumor infiltrating lymphocyte technology for various oncology indications. Robert's earlier career includes significant contributions at Insys Therapeutics, UCLA as a Post-Doctoral Scholar, and Children's Hospital Los Angeles, where expertise in pediatric neuro-oncology was developed. Academic credentials include a degree in Chemistry from the Massachusetts Institute of Technology, an M.D. from Joan & Sanford I. Weill Medical College of Cornell University, and a fellowship in Pediatric Hematology-Oncology from Yale School of Medicine.
This person is not in any offices
Zai Lab
5 followers
Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.